Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14): Bortezomib-Based Therapy without ASCT

被引：0
|
作者：
Reece, Donna E.
Rodriguez, Giovanni Piza [1 ]
Belch, Andrew [2 ]
Szwajcer, David [3 ,4 ]
Kovacs, Michael J. [5 ]
Shustik, Chaim [6 ]
Bahlis, Nizar J. [7 ]
White, Darrell J. [8 ]
Pantoja, Mariela [1 ]
Chen, Christine
Kukreti, Vishal
Anglin, Peter [9 ]
Trudel, Suzanne [10 ]
机构：
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[3] CancerCare Manitoba, Dept Hematol, Winnipeg, MB, Canada
[4] Univ Manitoba, Winnipeg, MB, Canada
[5] Victoria Hosp, London Hlth Sci Ctr, London, ON N6A 4G5, Canada
[6] McGill Univ, Div Haematol, Ctr Hlth, Montreal, PQ, Canada
[7] Univ Calgary, Div Hematol, Calgary, AB, Canada
[8] Queen Elizabeth 2 Hlth Sci Ctr, Div Hematol, Halifax, NS, Canada
[9] Southlake Reg Canc Ctr, Newmarket, ON, Canada
[10] Princess Margaret Hosp, McLaughlin Ctr Mol Med, Toronto, ON M4X 1K9, Canada
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：822 / 822
页数：1
相关论文
共 50 条
  • [31] Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study
    Cohen, Yael C.
    Joffe, Erel
    Benyamini, Noam
    Dimopoulos, Meletios A.
    Trestman, Svetlana
    Held, Viki
    Avivi, Irit
    Kastritis, Efstathios
    BLOOD, 2014, 124 (21)
  • [32] Low Level Of NF-Kb Activity Is Associated With Higher Response Rate To Bortezomib-Based Induction Therapy In Patients With Newly Diagnosed Multiple Myeloma
    Magrangeas, Florence
    Moreau, Philippe
    Campion, Loic
    Avet-Loiseau, Herve
    Guerin, Catherine
    Gouraud, Wilfried
    Marit, Gerald
    Attal, Michel
    Caillot, Denis
    Facon, Thierry
    Hulin, Cyrille
    Benboubker, Lotfi
    Pegourie, Brigitte
    Minvielle, Stephane
    BLOOD, 2013, 122 (21)
  • [33] The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
    Tang, Hoi Ki Karen
    Fung, Chi Yeung
    Morgan, Gareth J.
    Kumar, Shaji
    Siu, Lisa
    Alvin, Ho Wan
    Yip, Sze Fai
    Lau, Ka Ngai Harry
    Lau, Chi Kuen
    Lee, Harold
    Leung, Kwan Hung
    Kho, Bonnie
    Wong, Howard
    Ngai, Cheong
    Hwang, Yu Yan
    Sim, Joycelyn
    Kwong, Yok Lam
    Chim, Chor Sang
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [34] Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy
    Joshua, D. E.
    Bashford, J.
    Szer, J.
    Horvath, N.
    Spencer, A.
    Hertzberg, M. S.
    Ashurst, E.
    Wade, J.
    Copeman, M. C.
    Prince, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Bortezomib and Dexamethasone Therapy for Newly Diagnosed Patients With Multiple Myeloma Complicated by Renal Impairment
    Li, Jian
    Zhou, Dao-Bin
    Jiao, Li
    Duan, Ming Hui
    Zhang, Wei
    Zhao, Yong Qiang
    Shen, Ti
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (05): : 394 - 398
  • [36] Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan plus ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study
    Reece, Donna E.
    Rodriguez, Giovanni Piza
    Pantoja, Mariela A.
    White, Darrell J.
    Venner, Christopher P.
    Stakiw, Julie
    Sebag, Michael
    Comeau, Terrance
    Song, Kevin
    Roy, Jean
    Louzada, Martha L.
    McCurdy, Arleigh
    Kukreti, Vishal
    Trudel, Suzanne
    Prica, Anca
    Tiedemann, Rodger E.
    Paul, Harminder K.
    Chen, Christine I.
    BLOOD, 2019, 134
  • [37] Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
    Zhai, Yujia
    Yuan, Dai
    Ge, Xueling
    Hu, Shunfeng
    Li, Peipei
    Fang, Xiaosheng
    Li, Ying
    Zhou, Xiangxiang
    Wang, Xin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
    Syed, Yahiya Y.
    DRUGS, 2017, 77 (13) : 1473 - 1480
  • [39] Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
    Yahiya Y. Syed
    Drugs, 2017, 77 : 1473 - 1480
  • [40] Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients
    Niesvizky, Ruben
    Flinn, Ian W.
    Rifkin, Robert M.
    Gabrail, Nashat Y.
    Charu, Veena
    Clowney, Billy
    Essell, James
    Gaffar, Yousuf A.
    Warr, Thomas A.
    Neuwirth, Rachel
    Corzo, Deyanira
    Reeves, James A.
    BLOOD, 2010, 116 (21) : 272 - 272
12345